Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients
Phase of Trial: Phase II
Latest Information Update: 05 May 2017
At a glance
- Drugs Ambrisentan (Primary)
- Indications Congenital heart defects
- Focus Pharmacokinetics
- 02 May 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2018.
- 02 May 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2018.
- 03 Aug 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.